Anthropic生命科学团队近日宣布，已与BigHat Biosciences、Bristol Myers Squibb、Divergence Labs、Enveda、Generate Biomedicines及The Column Group (TCG)建立深度合作，旨在利用Claude AI加速新药研发的分子设计、抗体生成、制造合规文件撰写及临床试验规划等环节 1。为扩大在医学领域的应用范围，Anthropic还推出了Claude Science工作台，提供生命科学家专用积分，启动生命科学验证计划并招募开放客座研究员 1。此外，该公司已完成对初创企业Mithril Medicine的收购，其创始人Cody Tranbarger曾借助Claude在不到18个月内将一种肌营养不良症潜在疗法从概念推进至小鼠实验有效阶段，预计最快于2028年底启动人体临床试验 1。
在具体技术突破方面，多家合作伙伴展示了显著的效率提升与设计优化成果 1。Generate Biomedicines利用Claude提出的新CAR T细胞疗法设计比标准版本短约70%，实验室测试显示免疫细胞产生受体数量增加约10倍且杀瘤效率更高 1。Divergence Labs通过Claude自主生成了约35,000个用于食物过敏治疗的抗体设计，初步筛选发现3个能结合IgE及20个能剥离IgE的设计 1。BigHat Biosciences借助AI优化抗体片段，最佳版本结合力提高10倍以上，热稳定性提升18°C，聚集速度减慢超过100倍 1。Enveda案例中，Claude审查1,061页文档发现了人类审阅者遗漏的7个问题，使人工审查时间减少89%，并将传统需3个月的监管文件起草工作压缩至4小时 1。
在战略投资与临床规划层面，The Column Group与Anthropic合作成立新公司Pleiades，利用Claude评估45个靶点-疾病对以运行更多复杂的药物项目 1。Bristol Myers Squibb则使用Claude分析专有数据、制定临床研究计划并评估成功概率，其代表Michael Pourdehnad MD对此给予了评价 1。
Anthropic’s life sciences team has established deep collaborations with six pharmaceutical and biotechnology companies to leverage the Claude AI model across various stages of drug development, including molecular design, antibody generation, manufacturing compliance documentation, and clinical trial planning. 1 The partnering firms include BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group (TCG). 1 As part of its broader expansion into medical applications, Anthropic also acquired the startup Mithril Medicine and launched the Claude Science workspace, which provides life scientists with Claude credits, initiates a validation program for life sciences, and opens recruitment for guest researchers. 1
Significant technical breakthroughs have emerged from these partnerships, demonstrating substantial reductions in time and improvements in efficacy. 1 In a case study with Generate Biomedicines, a new CAR T-cell therapy design proposed by Claude was approximately 70% shorter than standard versions; laboratory tests revealed that immune cells produced about ten times more receptors, resulting in higher tumor-killing efficiency. 1 Similarly, BigHat Biosciences used Claude to optimize antibody fragments, achieving a version with over tenfold increased binding affinity, an 18°C improvement in thermal stability, and aggregation speeds slowed by more than 100 times. 1 Divergence Labs employed Claude to autonomously generate around 35,000 antibody designs for treating food allergies, identifying three candidates capable of binding IgE and twenty others able to strip IgE in preliminary tests. 1
Beyond experimental design, Claude is streamlining regulatory processes and corporate strategy. 1 At Enveda, the AI reviewed 1,061 pages of documentation, uncovering seven issues missed by human reviewers and reducing manual review time by 89%; it also drafted two regulatory documents, one of which took only four hours compared to the traditional three-month timeline. 1 The Column Group collaborated with Anthropic to establish a new company called Pleiades, utilizing Claude to evaluate 45 target-disease pairs and run more complex drug projects. 1 Bristol Myers Squibb is using Claude to analyze proprietary data, develop clinical research plans, and assess success probabilities, with Michael Pourdehnad MD providing positive evaluations of the process. 1 Meanwhile, Mithril Medicine founder Cody Tranbarger reported using Claude to advance a potential therapy for muscular dystrophy from concept to effective results in mouse models in under 18 months, with human clinical trials expected to begin as early as the end of 2028. 1
评论
还没有评论，欢迎留下第一条。